News
Oma Fertility introduces shared egg freezing programme to support aspiring parents
Patients who freeze their eggs and donate a portion will be offered the procedure at no cost
Oma Fertility has announced a shared egg freezing programme to “democratise” access to egg freezing services and meet growing demand for egg donors.
The programme will enable patients in the US to freeze and store their eggs for free, including medications, and donate a portion of the eggs retrieved to the the clinic’s egg donor programme to help others on their journey to parenthood.
Those who make a donation will receive the entire procedure at no cost.
The programme is being introduced at a time when egg freezing services are in high demand and the need is greater than ever.
The American Society of Reproductive Medicine (ASRM) estimates egg freezing increased a staggering 2,695 per cent from 2009 to 2018 and shows no signs of slowing down.
By 2025, almost 10 million couples will encounter problems having a baby, and approximately 20 per cent will rely on IVF over the next two decades.
Today, the national average cost for one complete cycle of egg freezing, including ultrasound monitoring, doctor supervision, and injectable medications, is upwards of US$14,000, not including the supplemental, annual cost for egg storage which can range anywhere from US$500 – US$1,000 per year.
Gurjeet Singh, co-founder, and CEO of Oma Fertility, said: “We understand these costs are out of reach for many.
“Our empathetic approach to affordable and accessible fertility care through programs like this provides our patients with the opportunity to plan for their own family while making parenthood a possibility for those who aren’t able to conceive on their own.”
Those who wish to apply for the programme must complete a donor application and an initial doctor consultation. If accepted, the US$9,500 egg freezing procedure, with five years of storage, will be offered at no cost.
Oma Fertility opened its first fertility clinic in Santa Barbara, California, in 2021 and has plans to expand nationally through 2023.
Last month the company announced a partnership with the digital pharmacy service Alto to offer prescription delivery and telehealth services to support patients through “strict and intimidating medication regimens”.
⬇️ You may also like ⬇️
How to prepare for an egg freezing consultation
The Women’s Health Innovation Summit (WHIS), the event uniting the global women’s health ecosystem, has just announced 18 new speakers joining the agenda for its 2026 summit, taking place October 13–15 at Encore Boston Harbor.
The latest additions bring further depth across pharma, clinical research, health systems, venture, and policy, reinforcing WHIS’s role as the only platform where the full women’s health ecosystem convenes under one roof.
Newly confirmed speakers include:
- Kelle Moley, MD – VP, Women’s Health Early Phase Clinical Development, Cardiometabolic Research, Eli Lilly & Company
- Justine Levin-Allerhand – Executive Partner, Chief Corporate Development Officer & COO, Flagship Labs, Flagship Pioneering
- Sebnem Yildirimoglu, MD, PMP – Executive Director, Women’s Health Strategy, Premier Research
- Terri Stewart – Head of Global Healthcare & Government Affairs, EMD Serono
- Dr. Morag Grassie – Executive Director, Blavatnik Fund for Innovation, Yale
- Sandra Butler – Director, Design Impact, Mass General Brigham
- Zhenya Lindgardt – Chief Executive Officer, Sera Prognostics
- Sadie Morahan – Head of US Revenue, Withings Health Solutions
- Angela Drew, PhD – Vice President, Regulatory Strategy, Premier Research
- Dr. Stephanie Lahr – CMIO, Aqurio
- Michelle Andrews – Contributing Writer, KFF Health News
- Charlotte Williams – CEO, My Bump Hub
- Clint Dart, MS – Director, NIH Women’s Health Data Coordinating Center, Premier Research
- Cass Sanford – US Venture Advisor, FemTech Lab
- Megan Mukuria – Founder & CEO, ZanaAfrica
- Tiffany Inglis, MD, FACOG – Chief Medical Officer, Sera Prognostics
- Angelean Hendrix, PhD – Vice President, Pharmacometrics and MIDD, Premier Research
- Amanda Ducach – CEO & Co-founder, EmaEQ
“WHIS is where the women’s health industry comes together to take action,” said Poppy Howard-Wall, Event Director at WHIS.
“This latest wave of speakers reflects exactly the kind of cross-sector expertise our attendees expect – from global pharma and clinical research leadership to venture, health systems, and grassroots innovation.
“It’s this breadth that makes WHIS the room where things actually move forward.”
Bringing the Full Ecosystem Together
These additions join a growing 2026 agenda spanning four content tracks that reflect the full lifecycle of healthcare innovation, from early-stage research and development through to patient delivery, system transformation, and commercial scale.
Attendees can expect over 1,000 senior decision-makers, 120+ expert speakers, four dedicated stages, and more than 10 hours of curated 1:1 meetings.
Full speaker and agenda details are available at whisusa.com/speakers-2026.
About WHIS
The Women’s Health Innovation Summit is the only platform uniting the full women’s health ecosystem – providers, payers, employers, pharma leaders, investors, and innovators -to increase deal flow, expand reimbursement, improve access, and deliver better outcomes for women at every stage of life.
Millions of women who have missed cervical screening in England will be offered free NHS home HPV tests.
The initiative is aimed at women who are not up to date with screening, with NHS estimates suggesting as many as 4 million have fallen behind.
The home kits contain a swab for collecting a vaginal sample, which is returned to the NHS free of charge and tested in a laboratory for high-risk human papillomavirus (HPV).
If high-risk HPV is detected through a home test, patients will be asked to attend a cervical screening appointment with a clinician.
HPV is a group of viruses that can be passed on through sexual contact and cause no symptoms. About 13 high-risk types are known to cause 99.7 per cent of cervical cancers.
Starting on Tuesday, eligible women aged between 30 and 65 who have not attended screening appointments will receive invitations through the NHS app, text message, email or letter.
They will then be able to order a testing kit through the NHS app or website.
The scheme is part of the NHS’s target to eliminate cervical cancer by 2040.
Dr Sue Mann, national clinical director for women’s health at NHS England, said: “Screening saves thousands of lives each year by preventing cancers and catching them earlier, but only around two-thirds of women are attending cervical screening appointments when invited by the NHS.
“Offering millions of women an alternative test they can do from the comfort of their own homes will be a gamechanger – making it easier than ever for them to get tested for HPV.”
Women aged between 24 and 64 are invited for cervical screening every five years, or more often if HPV is detected.
NHS England figures show 68.8 per cent of eligible women are up to date with cervical screening, below the 80 per cent target.
Mann said: “There are lots of reasons that may stop women from getting their cervical screening – embarrassment, lack of time, or worries about discomfort – and these kits provide a discreet and convenient option we hope will encourage more women to take up the life-saving test.
“So, if you’re invited to take part, please order a test – it’s a simple swab you can do at home in minutes.”
Athena Lamnisos, chief executive of the Eve Appeal, welcomed the move, saying that self-testing at home would be a “step-change” for many women.
Michelle Mitchell, chief executive of Cancer Research UK, said: “Cervical screening is a powerful tool that saves lives – it can prevent cervical cancer or spot it at an earlier stage when treatment is more likely to be successful.
“While it’s best for cervical screening to be done by a nurse or doctor, there are barriers that make it challenging for some people to attend. At-home HPV self-testing kits will help more people take part in a way that works for them.”
Health secretary Yvette Cooper said the aim was to make it as easy and convenient as possible for women to keep up with their screening.
She said: “This is the future NHS we are building – there for all of us when we need it, and acting as early as possible to stop preventable deaths.”
Nearly a quarter of women often miss work because of menstrual symptoms, according to a survey examining hormonal health among women in full-time work in Ireland.
The survey looked at the impact of menstruation, fertility and motherhood, and perimenopause and menopause.
Research from The Menopause Hub found more than one in three women who had not disclosed a menstrual health issue at work said the lack of a clear workplace policy was the reason.
More than a quarter said they did not think their concerns would be taken seriously, while 22 per cent cited embarrassment and 18 per cent feared being judged.
Nearly half of respondents said better workplace support would have made them feel less stressed, while 40 per cent said it would have made them feel more valued. Some 36 per cent said they would have felt more comfortable speaking up.
Some 76 per cent of women surveyed said they experienced menstrual health issues, with 23 per cent of those often missing work because of symptoms.
Nearly half of respondents, 49 per cent, said they felt uncomfortable talking about menstruation at work.
One respondent said: “As a woman, we try to get through the day, sometimes in pain that can’t be seen. We feel emotionally and physically drained.”
The research also found that 62 per cent of those who experienced baby loss reported a moderate or significant impact on work attendance.
More than half of respondents who experienced depression during pregnancy also reported a moderate or significant impact on attendance.
Some 63 per cent of mothers said it was “difficult” to return to work after pregnancy, while nearly half said their maternity pay arrangement had negatively affected their financial wellbeing.
One respondent said: “I almost walked away. The only reason I stayed was because I had to provide for my family.”
The survey also found that nearly half of respondents said menopause had some impact on their attendance, while more than six in 10 reported an impact on their work performance.
Some 44 per cent of women said they were “uncomfortable” discussing perimenopause and menopause at work.
One person said they were “already terrified of losing my job at my age:
“I need to just struggle through this without support or acknowledgement. That’s basically workplace discrimination.”
The Menopause Hub chief executive Loretta Dignam said women’s hormonal health has been treated as a “private or personal issue” for too long, “when the reality is that it has a very real impact on women’s working lives”.
“The fundamental point is that women are not ‘mini men.’
“Our biology is different, and workplaces that were largely designed around a male model of health and working life need to evolve to recognise that.
“What is striking is how many women continue to show up, perform, push through and progress at work while managing significant physical and emotional symptoms, often without the policies, understanding or practical support they need,” Dignam said.
She added that because expectations are changing, Gen Z and Gen Alpha employees will be “far less willing than previous generations to accept workplaces that ignore their health and wellbeing”.
Entrepreneur2 weeks agoApplications close August 18 for Women’s Health Innovation Summit 2026 Innovation Showcase
Mental health2 weeks agoThird of women unaware of perimenopause mental health impact
Fertility1 week agoChelsea FC Women to launch first-of-its-kind player fertility fund
Menopause2 weeks agoMenopausal hormone therapy may lower dementia risk, study suggests
Opinion1 week agoanna perimenopause app launches across 39 markets
Hormonal health2 weeks agoWe are wrapping our children in plastic and calling it care
Pregnancy2 weeks agoChemicals in plastics may be linked to high blood pressure during pregnancy
News2 weeks agoWomen with endometriosis face 46% higher risk of type 2 diabetes – study